Avalon Ventures Adjusts Janux Therapeutics Stake

TL;DR

Avalon Ventures XI now holds 14.9% of Janux Therapeutics after filing an amendment.

AI Summary

Avalon Ventures XI, L.P. and its affiliates have amended their Schedule 13D filing regarding Janux Therapeutics, Inc. as of June 5, 2024. The filing indicates a change in beneficial ownership, with the group now holding 10,420,000 shares of common stock, representing approximately 14.9% of the outstanding shares. This filing is an amendment to a previous filing, suggesting ongoing activity or adjustments in their investment strategy.

Why It Matters

This filing signals a potential shift in the ownership structure of Janux Therapeutics, which could influence the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Changes in significant beneficial ownership can indicate shifts in investor sentiment or strategy, potentially impacting stock volatility.

Key Numbers

• 10,420,000 — Shares Owned (Represents significant beneficial ownership by Avalon Ventures XI, L.P. and affiliates.)
• 14.9% — Ownership Stake (Indicates the percentage of Janux Therapeutics' outstanding shares held by the filing group.)

Key Players & Entities

• Avalon Ventures XI, L.P. (company) — Filing entity
• Janux Therapeutics, Inc. (company) — Subject company
• 10,420,000 (dollar_amount) — Number of shares beneficially owned
• 14.9% (dollar_amount) — Percentage of outstanding shares owned
• June 5, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 47103
• $54.75 — of block trades at prices ranging from $54.75 to $55.07 per share (a weighted-average
• $55.07 — trades at prices ranging from $54.75 to $55.07 per share (a weighted-average price of

Filing Documents

• tm2416571d1_sc13da.htm (SC 13D/A) — 235KB
• tm2416571d1_ex99a.htm (EX-99.A) — 11KB
• 0001104659-24-068766.txt ( ) — 248KB

Purpose of Transaction

Item 4. Purpose of Transaction

of the Original Schedule 13D is hereby amended and supplemented

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraphs at the end of Item 4: On June 3, 2024, Avalon Ventures sold 677,279 shares of Common Stock, ABV SPV sold 691,525 shares of Common Stock and ABV I sold 131,196 shares of Common Stock, each in a series of block trades at prices ranging from $54.75 to $55.07 per share (a weighted-average price of $54.75 per share).

Interest in Securities of the

Item 5. Interest in Securities of the Issuer (a)– (b). The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of June 5, 2024: Reporting Persons Shares Held Directly Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Beneficial Percentage of Class (6) Avalon Ventures (1) 3,271,216 3,271,216 3,271,216 3,271,216 6.3 % ABV SPV (2) 3,340,018 3,340,018 3,340,018 3,340,018 6.4 % ABV I (3) 633,673 633,673 633,673 633,673 1.2 % Avalon XI GP (1) 3,271,216 3,271,216 3,271,216 6.3 % ABV SPV GP (2) 3,340,018 3,340,018 3,340,018 6.4 % ABV GP (3) 633,673 633,673 633,673 1.2 % Kinsella (1) 6,966 6,966 3,271,216 6,966 3,271,216 3,278,182 6.3 % Levandov (1) 5,651 5,651 3,271,216 5,651 3,271,216 3,276,867 6.3 % Bohrmann (1) 3,754 3,754 3,271,216 3,754 3,271,216 3,274,970 6.3 % Lichter (1) (2) (3) (4) 59,583 59,583 7,244,907 59,583 7,244,907 7,304,490 14.1 % Reardon (2) (3) (5) 486,081 486,081 3,973,691 446,049 3,973,691 4,459,772 8.5 % Duron (3) 92,630 92,630 633,673 92,630 633,673 726,303 1.4 % Madigan (3) 107,810 107,810 633,673 107,810 633,673 741,483 1.4 % (1) Includes 3,271,216 shares of Common Stock held by Avalon Ventures. Avalon XI GP is the general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. Kinsella, Levandov, Bohrmann and Lichter are the managing members of Avalon XI GP and share voting and investment power with respect to the shares held by Avalon Ventures. (2) Includes 3,340,018 shares of Common Stock held by ABV SPV. ABV SPV GP is the general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV. Lichter and Reardon are the managing

View Full Filing

View this SC 13D/A filing on SEC EDGAR